Evidence map›Paper›PMID 26155434›Full record

ArticleAmerican journal of clinical and experimental immunology2015

Investigation of IL-21 gene polymorphisms (rs2221903, rs2055979) in cases with multiple sclerosis of Azerbaijan, Northwest Iran.

Tohid Gharibi, Tohid Kazemi, Mohammad Reza Aliparasti, Mehdi Farhoudi, Shohreh Almasi, Rashedeh Dehghanzadeh, Narges Seyfizadeh, Zohreh Babaloo

Open access · greenAbstract read
In one paragraph

Article in American journal of clinical and experimental immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tohid GharibiDrug Applied Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Immunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Tohid KazemiImmunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Mohammad Reza AliparastiDrug Applied Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Immunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Mehdi FarhoudiNeuroscience Research Center, Tabriz University of Medical Sciences Tabriz, Iran.
Shohreh AlmasiImmunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Rashedeh DehghanzadehDepartment of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Narges SeyfizadehImmunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Zohreh BabalooDrug Applied Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Immunology Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Neuroscience Research Center, Tabriz University of Medical Sciences Tabriz, Iran ; Department of Immunology, Tabriz University of Medical Sciences Tabriz, Iran.
Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the Central Nervous System that is immunologically mediated in genetically susceptible individuals. IL-21, a cytokine produced by TCD4(+) cells, particularly by Th-17 cells, is believed to play an important role in the MS pathogenesis.

objectiveThis study was performed to investigate the impact of genetic polymorphisms in IL-21 gene on MS susceptibility and clinical profiles.

methodsSeventy Iranian patients with clinically definite relapsing-remitting MS and 110 age, sex and ethic matched controls were genotyped for IL-21 gene polymorphisms using PCR-RFLP method.

resultsOur results showed that the IL-21 rs2221903 SNP is not polymorphic in our population. Also, the allelic and genotypic frequencies of the IL-21 rs2055979 did not differ significantly between the MS patients and controls (P = 0.413 and P = 0.565 respectively, and OR = 1.122, 95% CI = 0.79-1.87 for T allele). However, our results showed that IL-21 rs2055979 (G/T) T allele positive (TT+GT) MS patients had lower (PI ≤ 1.5) disease progression compared to rs2055979 T allele negative (GG) patients (P = 0.009).

conclusionOur results showed that no outstanding association exists between IL-21 alleles and susceptibility to MS. However, our clinical analysis showed significant association of IL-21 gene polymorphism with the progression of multiple sclerosis disease. Our results indicate that the G allele promotes, or the T allele protects against disease progression. To clarify the role of IL-21 rs2055979 in MS pathogenesis, further comprehensive studies with larger sample sizes among different ethnicity populations are recommended.

Indexed as

interleukin-21Multiple sclerosispolymorphismprogression index

Identifiers

PMID26155434
PMCPMC4494115
OpenAlexW2416124825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.